| (Values in U.S. Thousands) | Nov, 2025 | May, 2025 | Feb, 2025 | Nov, 2024 | May, 2024 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -597 | -381 | -583 | -372 | -381 |
| Net Income Growth | -56.90% | +34.76% | -56.67% | +2.31% | +9.58% |
Algernon Health Inc (AGN.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Algernon Health Inc is a clinical-stage pharmaceutical development company focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), and stroke, including a program utilizing N,N-Dimethyltryptamine (DMT). Drug re-purposing (also known as re-profiling, re-tasking, or therapeutic switching) involves applying approved drugs and compounds to treat diseases. In addition, the Company is entering the Alzheimer's disease (AD) diagnostic market segment and plans to establish a network of dedicated neuroimaging medical clinics in North America, utilizing FDA-cleared, brain-specific PET scanners to focus on early-stage detection of the disease.